Search research articles
Contact Us
Filters
Showing results (191-200 of 397) with videos related to
Page
of 40
Sort By:
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Oncotarget
|
February 26, 2013
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
Gerald S Falchook, Aung Naing, David S Hong, et al.
Investigational New Drugs
|
May 21, 2015
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
Rabih Said, Razelle Kurzrock, Aung Naing, et al.
Breast Cancer Research : BCR
|
August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
Natalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Cancer
|
January 24, 2025
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers
Jibran Ahmed, Filip Janku, Daniel D Karp, et al.
Tropical Medicine and Infectious Disease
|
April 27, 2026
Series 2: Invisible Threats: A Global Scoping Review of Risk Factors for Tuberculosis Infection
Sonia Menon, Anthony D Harries, Riitta A Dlodlo, et al.
American Journal of Physical Anthropology
|
September 21, 2010
Talar morphology, phylogenetic affinities, and locomotor adaptation of a large-bodied amphipithecid primate from the late middle eocene of Myanmar
Laurent Marivaux, K Christopher Beard, Yaowalak Chaimanee, et al.
Experimental Hematology & Oncology
|
April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Cancer
|
May 2, 2023
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer
Mehmet Altan, Janet Tu, Denái R Milton, et al.
Molecular Cancer Therapeutics
|
March 5, 2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Roman Groisberg, Jason Roszik, Anthony P Conley, et al.
Page
of 40
Search research articles
Search
Showing results (191-200 of 397) with videos related to
Sort By:
Page
of 40
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Oncotarget
|
February 26, 2013
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
Gerald S Falchook, Aung Naing, David S Hong, et al.
Investigational New Drugs
|
May 21, 2015
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
Rabih Said, Razelle Kurzrock, Aung Naing, et al.
Breast Cancer Research : BCR
|
August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
Natalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Cancer
|
January 24, 2025
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers
Jibran Ahmed, Filip Janku, Daniel D Karp, et al.
Tropical Medicine and Infectious Disease
|
April 27, 2026
Series 2: Invisible Threats: A Global Scoping Review of Risk Factors for Tuberculosis Infection
Sonia Menon, Anthony D Harries, Riitta A Dlodlo, et al.
American Journal of Physical Anthropology
|
September 21, 2010
Talar morphology, phylogenetic affinities, and locomotor adaptation of a large-bodied amphipithecid primate from the late middle eocene of Myanmar
Laurent Marivaux, K Christopher Beard, Yaowalak Chaimanee, et al.
Experimental Hematology & Oncology
|
April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Cancer
|
May 2, 2023
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer
Mehmet Altan, Janet Tu, Denái R Milton, et al.
Molecular Cancer Therapeutics
|
March 5, 2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Roman Groisberg, Jason Roszik, Anthony P Conley, et al.
Page
of 40